Biomx Ltd is a biotechnology company focused on developing innovative therapies that harness the power of bacteriophage, a type of virus that specifically targets and kills bacteria
The company primarily aims to treat diseases caused by specific bacterial infections, particularly those that are resistant to traditional antibiotics. By utilizing phage-based treatments, Biomx is working to address significant medical challenges in various conditions, including gastrointestinal disorders and other diseases driven by harmful bacteria, with the ultimate goal of improving patient outcomes and enhancing the overall landscape of antimicrobial therapies.
Companies Reporting Before The Bell • Acuity Brands (NYSEAYI) is projected to report quarterly earnings at $3.25 per share on revenue of $907.75 million.
BiomX shares are trading higher Wednesday after the company announced it has entered into a definitive merger agreement with Adaptive Phage Therapeutics, Inc. The acquisition is expected to close within the next 30 days, subject to the satisfaction of the closing conditions.
Shares of Patterson Companies, Inc. (NASDAQPDCO) moved lower during Wednesday’s session after the company reported worse-than-expected second-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.
BiomX Inc (NYSEPHGE) released safety and efficacy results from Part 2 of the Phase 1b/2a trial of BX004 for chronic pulmonary infections caused by Pseudomonas aeruginosa (P.
